AVEXA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS Melbourne,...

AVEXA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS Melbourne, Australia, 30 June 2009: Avexa Limited (ASX: AVX) today announced the appointment of Lawrence
Gozlan to its Board of Directors, replacing Dr John Sime who is retiring from the board. Dr Sime was appointed
to the board as a non-executive director in June 2007, and Mr Gozlan will replace him in this capacity effective
immediately.

"We are thrilled to welcome Lawrence to our Board of Directors. His background in the life science industry as
both a leading analyst and investor brings a unique and important perspective to our organisation, and we look
forward to his guidance and leadership as we continue to grow," said Nathan Drona, chairman of Avexa. "I
would also like to acknowledge John's significant contribution to the Avexa board over the last two years and
wish him well for his future."

"Avexa is at a critical juncture with apricitabine currently in Phase III trials and the remainder of the pipeline
progressing on track. I am excited to work with the company's management and board of directors as we look to
move the products forward through development," stated Lawrence Gozlan.

Lawrence Gozlan is the CEO and founder of Scientia Capital, a specialised global investment fund focused
exclusively on life science. Prior to Scientia, Mr Gozlan was responsible for the largest biotechnology investment
portfolio in Australia as the institutional biotechnology analyst at Queensland Investment Corporation (QIC), a
fund manager with over $50 billion AUD under management. He was also the senior biotechnology sell-side
analyst on the equities team at Foster Stockbroking, and had corporate finance experience advising life science
companies at Deloitte.

About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of small
molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects
including apricitabine (ATC), its HIV integrase program, its HCV polymerase program and an antibiotic program
for antibiotic-resistant bacterial infections. The Company's lead program, ATC, is an anti-HIV drug that has
successfully completed the 96 week dosing of its Phase IIb trial and is currently in Phase III trials worldwide. For more information:

Dr Julian Chick Stephen Kerr Chief Executive Officer CFO & Company Secretary +61 3 9208 4300 + 61 3 9208 4300
AU: Investor Relations US: Investor Relations Sabrina Antoniou Remy Bernarda Blueprint Life Science Group Blueprint Life Science Group + 61 2 9519 5537 + 1 415 375 3340 x2022 www.avexa.com.au